clement, Author at BaseLaunch

Features

BaseLaunch funds four healthcare ventures

BaseLaunch supports carefully selected ventures in two phases. After a very intense pressure test period, four projects were selected for Phase II of our second…

clement22.01.2019

Features

Applications for 2019 are now open

We are excited to be open for new applications. We are looking for people and projects with breakthrough healthcare innovations mainly in the field of…

clement22.01.2019

Features

Looking for an experienced drug developer to join an emerging biotech

A company we are supporting is currently finalizing a substantial Series A round with leading European investors. To complement the team, they are currently looking…

clement22.01.2019

Features

Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own

clement18.12.2018

Features

A Harvard Professor Made $400 Million in Moderna’s Biotech IPO

clement13.12.2018

Features

Black Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes

clement11.12.2018

Features

Infographic: The Basel Biotech & Pharma Ecosystem

To develop a scientific discovery into a life-changing drug or technology, it takes experts from various fields. We have collaborated with Labiotech.eu to paint a…

clement11.12.2018

Interviews

“We help to translate research into product, which benefits patients or society at large”

Herbert Reutimann, the CEO of Unitectra, the joint technology transfer organization of the Universities of Basel, Bern and Zurich, talks about the ways in which…

clement11.12.2018

Features

Can a biotech unicorn break into the record books with a $600M IPO? Stéphane Bancel has a fortune riding on the answer

clement29.11.2018

Features

Roivant raised USD 200 million, now valued at USD 7 billion

The Basel-based pharmaceutical company Roivant Sciences has raised USD 200 million in a funding round. As a result, the company is now valued at an…

clement19.11.2018

clement

BaseLaunch funds four healthcare ventures

Applications for 2019 are now open

Looking for an experienced drug developer to join an emerging biotech

Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own

A Harvard Professor Made $400 Million in Moderna’s Biotech IPO

Black Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes

Infographic: The Basel Biotech & Pharma Ecosystem

“We help to translate research into product, which benefits patients or society at large”

Can a biotech unicorn break into the record books with a $600M IPO? Stéphane Bancel has a fortune riding on the answer

Roivant raised USD 200 million, now valued at USD 7 billion

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us